Globe Newswire11.02.18
B. Braun Medical Inc. has introduced its Surecan Safety II Port Access Needles, a safety engineered needle for accessing implanted intravenous ports. The safety mechanism offers a unique visual confirmation when successfully engaged. The non-coring port access needles are suitable for power injections to 325 psi.1
The Surecan Safety II has a manually activated safety mechanism that is designed to provide visual confirmation with a green dot that is visible through the clear bottom plate. The Surecan Safety II also is designed to provide tactile confirmation upon activation. The safety mechanism is designed to reduce the risk of accidental needlestick injuries by shielding the needle tip during and after removal.
The single-use Surecan Safety II is intended for insertion into the septum of a subcutaneously implanted port for the infusion of fluids and drugs, as well as blood sampling. The needles are available in sizes from 19 gauge to 22 gauge and have a useable needle length ranging from 0.5 inches to 1.5 inches (12 mm to 38 mm). They are available with or without a Y-site and the Y-site version includes a pre-attached CARESITE luer access device.
In addition to the green dot safety mechanism, Surecan Safety II’s features include:
“Surecan Safety II’s small size and design features can enhance the user’s safety and experience,” said Steve Weber, director of Marketing for IV and Vascular Access Systems at B. Braun. “The non-coring needle’s nonabsorbent pad and closed cell materials are designed to reduce the risk of needlestick injuries.”
B. Braun Medical Inc., a leader in infusion therapy and pain management, develops, manufactures, and markets medical products and services to the healthcare industry. Other key product areas include nutrition, pharmacy admixture and compounding, ostomy and wound care, and dialysis. The company is committed to eliminating preventable treatment errors and enhancing patient, clinician and environmental safety. B. Braun Medical is headquartered in Bethlehem, Pa., and is part of the B. Braun Group of Companies in the United States, which includes B. Braun Interventional Systems, Aesculap, and CAPS.
Globally, the B. Braun group of companies employs more than 61,000 employees in 64 countries.
References
1. Data on file.
2. Data on file.
The Surecan Safety II has a manually activated safety mechanism that is designed to provide visual confirmation with a green dot that is visible through the clear bottom plate. The Surecan Safety II also is designed to provide tactile confirmation upon activation. The safety mechanism is designed to reduce the risk of accidental needlestick injuries by shielding the needle tip during and after removal.
The single-use Surecan Safety II is intended for insertion into the septum of a subcutaneously implanted port for the infusion of fluids and drugs, as well as blood sampling. The needles are available in sizes from 19 gauge to 22 gauge and have a useable needle length ranging from 0.5 inches to 1.5 inches (12 mm to 38 mm). They are available with or without a Y-site and the Y-site version includes a pre-attached CARESITE luer access device.
In addition to the green dot safety mechanism, Surecan Safety II’s features include:
- A low profile and foam pad, designed to assist with the placement of a securement dressing.
- Flexible and ergonomic wings, designed to provide secure handling during insertion and removal of the needle.2
- A small, transparent, round base plate, designed to help increase stability and help visualize the placement of the needle.
“Surecan Safety II’s small size and design features can enhance the user’s safety and experience,” said Steve Weber, director of Marketing for IV and Vascular Access Systems at B. Braun. “The non-coring needle’s nonabsorbent pad and closed cell materials are designed to reduce the risk of needlestick injuries.”
B. Braun Medical Inc., a leader in infusion therapy and pain management, develops, manufactures, and markets medical products and services to the healthcare industry. Other key product areas include nutrition, pharmacy admixture and compounding, ostomy and wound care, and dialysis. The company is committed to eliminating preventable treatment errors and enhancing patient, clinician and environmental safety. B. Braun Medical is headquartered in Bethlehem, Pa., and is part of the B. Braun Group of Companies in the United States, which includes B. Braun Interventional Systems, Aesculap, and CAPS.
Globally, the B. Braun group of companies employs more than 61,000 employees in 64 countries.
References
1. Data on file.
2. Data on file.
